PCSK9:心血管钙化的新治疗靶点?
作者:
作者单位:

(南华大学心血管疾病研究所 动脉硬化学湖南省重点实验室 湖南省动脉硬化性疾病国际科技创新合作基地,湖南省衡阳市 421001)

作者简介:

龚熙,硕士研究生,研究方向为动脉粥样硬化及发病机制,E-mail:gx160481@163.com。通信作者唐志晗,博士,教授,博士研究生导师,研究方向为动脉粥样硬化及发病机制,E-mail:tangzhihan98@163.com。通信作者彭娟,博士,副教授,硕士研究生导师,研究方向为动脉粥样硬化及发病机制,E-mail:pengjuan98@sina.com。

基金项目:

国家自然科学基金项目(81770454);湖南省自然科学基金项目(2022JJ30510)


PCSK9:a new therapeutic target for cardiovascular calcification?
Author:
  • GONG Xi

    GONG Xi

    Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China
    在知网中查找
    在百度中查找
    在本站中查找
  • XIANG Qiong

    XIANG Qiong

    Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China
    在知网中查找
    在百度中查找
    在本站中查找
  • CHEN Yanyu

    CHEN Yanyu

    Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China
    在知网中查找
    在百度中查找
    在本站中查找
  • TANG Zhihan

    TANG Zhihan

    Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China
    在知网中查找
    在百度中查找
    在本站中查找
  • PENG Juan

    PENG Juan

    Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China
    在知网中查找
    在百度中查找
    在本站中查找
Affiliation:

Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China)

  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
    摘要:

    前蛋白转化酶枯草溶菌素9(PCSK9)是分泌型丝氨酸蛋白酶家族的第9个成员,由692个氨基酸组成,它能与低密度脂蛋白受体(LDLR)结合,导致循环中的低密度脂蛋白胆固醇(LDLC)水平升高,从而引发诸多心血管疾病,其与心血管钙化的关系近来受到关注。心血管钙化是心血管系统的一种异位矿化,以血管壁和血管瓣膜中产生矿物质沉积为主要特征,其发病机制与脂蛋白含量、血小板活性、基质囊泡(MV)释放及炎症反应有关,PCSK9可能通过上述途径参与心血管钙化的发生。因此,本文对PCSK9与心血管钙化之间的关系进行综述,并着重介绍了PCSK9通过不同途径影响心血管钙化的具体作用,有助于建立PCSK9在血管生物学中的新作用,并确定心血管钙化治疗的新分子机制。

    Abstract:

    Proprotein convertase subtilisin/kexin type 9 (PCSK9) comprised of 692 amino acids is the ninth member of protease family. It binds to the low-density lipoprotein receptor(LDLR), leading to elevated levels of circulating low-density lipoprotein cholesterol(LDLC), which can lead to a number of cardiovascular diseases, and among then the relationship with cardiovascular calcification has recently received attention. Cardiovascular calcification is a kind of ectopic mineralisation in the cardiovascular system, which is mainly characterised by the production of mineral deposits in the vascular wall and vascular valves, and its pathogenesis is related to lipoprotein content, platelet activity, matrix vesicle (MV) release and inflammation, through which PCSK9 may be involved in the occurrence of cardiovascular calcification.Therefore, this article reviews the relationship between PCSK9 and cardiovascular calcification, emphasizing the specific role of PCSK9 in affecting cardiovascular calcification through various pathways, assisting in setting up emerging applications of PCSK9 amid vessel biological science and recognize innovative molecular mechanisms for its treatment.

    参考文献
    [1] 朱钰钰, 张丹凤, 李欢, 等.血清锌、铜/锌比值与慢性肾脏病患者冠状动脉钙化的相关性.中国动脉硬化杂志, 2,0(12):1051-1057.ZHU Y Y, ZHANG D F, LI H, et al.Correlation of blood zinc, copper/ zinc ratio and coronary artery calcification in patients with chronic kidney disease.Chin J Arterioscler, 2,0(12):1051-1057.
    [2] LI W D, SU S A, CHEN J, MA H.Emerging roles of fibroblasts in cardiovascular calcification.J Cell Mol Med, 1,5(4):1808-1816.
    [3] ABIFADEL M, VARRET M, RABS J P.Mutations in pcsk9 cause autosomal dominant hypercholesterolemia.Nat Genet., 3,4(2):154-156.
    [4] GUO Y N, YAN B J, TAI S.Pcsk9:Associated with cardiac diseases and their risk factors? Arch Biochem Biophys, 1,4:108-717.
    [5] LUPO M G, BRESSAN A, DONATO M.Pcsk9 promotes arterial medial calcification.Atherosclerosis, 2,6:86-97.
    [6] PERROT N, MOSCHETTA D, BOEKHOLDT S M.Genetic inhibition of pcsk9, atherogenic lipoprotein concentrations, and calcific aortic valve stenosis.bioRxiv, 9,8.
    [7] PERROT N, VALERIO V, MOSCHETTA D.Genetic and in vitro inhibition of pcsk9 and calcific aortic valve stenosis.JACC Basic Transl Sci, 0,5(7):649-661.
    [8] ZHAO X, ZHANG H W, LI S.Association between plasma proprotein convertase subtisilin/kexin type 9 concentration and coronary artery calcification.Ann Clin Biochem, 8,5(1):158-164.
    [9] CAO Y X, JIN J L, SUN D.Circulating pcsk9 and cardiovascular events in fh patients with standard lipid-lowering therapy.J Transl Med, 9,7:1-11.
    [10] MENICHELLI D, GALARDO G, CAMMISOTTO V.Association of proprotein convertase subtilisin/kexin type 9 (pcsk9) levels with abnormally high ankle-brachial index in atrial fibrillation.Kardiol Pol, 3,1(4):381-387.
    [11] POSADAS-SNCHEZ R, VARGAS-ALARCN G, PREZMNDEZ .Increased carotid intima-media thickness in asymptomatic individuals is associated with the pcsk9 (rs2149041) gene polymor-phism in the mexican mestizo population:Results of the gea cohort.Life (Basel), 2,2(10):1531.
    [12] IKEGAMI Y, INOUE I, INOUE K.The annual rate of coronary artery calcification with combination therapy with a pcsk9 inhibitor and a statin is lower than that with statin monotherapy.NPJ Aging Mech Dis, 8,4(1):7.
    [13] LIANG D, LI C, TU Y M.Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound:A prisma-compliant meta-analysis.Medicine (Baltimore), 2,1(41):e31199.
    [14] KAPELOUZOU A, GERONIKOLOU S, LIDORIKI I.Tissue and serum biomarkers in degenerative aortic stenosis-insights into pathogenesis, prevention and therapy.Biology (Basel), 3,2(3):347.
    [15] IQBAL F, SCHLOTTER F, BECKER-GREENE D.Sortilin enhances fibrosis and calcification in aortic valve disease by inducing interstitial cell heterogeneity.Eur Heart J, 3,4(10):885-898.
    [16] GOETTSCH C, STRZELECKA-KILISZEK A, BESSUEILLE L.Tnap as a therapeutic target for cardiovascular calcification:a discussion of its pleiotropic functions in the body.Cardiovasc Res, 2,8(1):84-96.
    [17] MYASOEDOVA V A, RAVANI A L, FRIGERIO B.Novel pharmacological targets for calcific aortic valve disease:Prevention and treatments.Pharmacol Res, 8,6:74-82.
    [18] WANG W G, HE Y F, CHEN Y L.Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification:A prospective, cross sectional study.J Int Med Res, 6,4(4):865-874.
    [19] POGGIO P, SONGIA P, CAVALLOTTI L.Pcsk9 involvement in aortic valve calcification.J Am Coll Cardiol, 8,2(24):3225-3227.
    [20] SALAUN E, MAHJOUB H, DAHOU A.Hemodynamic deterioration of surgically implanted bioprosthetic aortic valves.J Am Coll Cardiol, 8,2(3):241-251.
    [21] GOETTSCH C, HUTCHESON J D, HAGITA S.A single injection of gain-of-function mutant pcsk9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification.Atherosclerosis, 6,1:109-118.
    [22] ELSEWEIDY M M, MOHAMED H E, ELRASHIDY R A.Inhibition of aortic calcification by policosanol in dyslipidemic rabbits is enhanced by pentoxifylline:potential role of pcsk9.J Cardiovasc Pharmacol Ther, 8,3(6):551-560.
    [23] GUO Y L, XU R X, ZHU C G.Policosanol attenuates statin-induced increases in serum proprotein convertase subtilisin/kexin type 9 when combined with atorvastatin.Evid Based Complement Alternat Med, 4,4:926087
    [24] FANTUS D, AWAN Z, SEIDAH N G.Aortic calcification:Novel insights from familial hypercholes-terolemia and potential role for the low-density lipoprotein receptor.Atherosclerosis, 3,6(1):9-15.
    [25] AWAN Z, DENIS M, BAILEY D.The ldlr deficient mouse as a model for aortic calcification and quantification by micro-computed tomography.Atherosclerosis, 1,9(2):455-462.
    [26] KRONENBERG F, MORA S, STROES E S.Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis:a european atherosclerosis society consensus statement.Eur Heart J, 2,3(39):3925-3946.
    [27] KAISER Y, TOORN J E, SINGH S S.Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification.Eur Heart J.2022;43(39):3960-3967.
    [28] CAPOULADE R, YEANG C, CHAN K L.Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels:Secondary Analysis of a Randomized Clinical Trial.JAMA Cardiol.2018;3(12):1212-1217.
    [29] O'DONOGHUE M L, FAZIO S, GIUGLIANO R P.Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.Circulation.2019;139(12):1483-1492.
    [30] ZHANG J, ZHENG B, ZHOU P P.Vascular calcification is coupled with phenotypic conversion of vascular smooth muscle cells through klf5-mediated transactivation of the runx2 promoter.Biosci Rep, 4,4(6):e00148.
    [31] IDELEVICH A, RAIS Y, MONSONEGO-ORNAN E.Bone gla protein increases hif-1α-dependent glucose metabolism and induces cartilage and vascular calcification.Arterioscler Thromb Vasc Biol, 1,1(9):e55-e71.
    [32] BOUCHAREB R, BOULANGER M C, TASTET L.Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis.Eur Heart J, 9,0(17):1362-1373.
    [33] CAMMISOTTO V, PASTORI D, NOCELLA C.Pcsk9 regulates nox2-mediated platelet activation via cd36 receptor in patients with atrial fibrillation.Antioxidants (Basel), 0,9(4):296.
    [34] CUI L, RASHDAN N A, ZHU D X.End stage renal disease-induced hypercal-cemia may promote aortic valve calcification via annexin vi enrichment of valve interstitial cell derived-matrix vesicles.J Cell Physiol, 7,2(11):2985-2995.
    [35] GOETTSCH C, HUTCHESON J D, AIKAWA M.Sortilin mediates vascular calcification via its recruitment into extracellular vesicles.J Clin Invest, 6,6(4):1323-1336.
    [36] ABDELBAKY A, CORSINI E, FIGUEROA A L,.Early aortic valve inflammation precedes calcification:a longitudinal fdg-pet/ct study.Atherosclerosis,5,8(2):165-172.
    [37] CHEN N X, O’NEILL K D, MOE S M.Matrix vesicles induce calcification of recipient vascular smooth muscle cells through multiple signaling pathways.Kidney Int, 8,3(2):343-354.
    [38] LENCEL P, DELPLACE S, PILET P.Cell-specific effects of tnf-α and il-1β on alkaline phosphatase:implication for syndesmophyte formation and vascular calcification.Lab Invest, 1,1(10):1434-1442.
    [39] AWAN Z, DENIS M, ROUBTSOVA A.Reducing vascular calcification by antiil-1β monoclonal antibody in a mouse model of familial hypercholes terolemia.Angiology, 6,7(2):157-167.
    [40] TINTUT Y, PATEL J, PARHAMI F.Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the camp pathway.Circulation, 0,2(21):2636-2642.
    [41] GIUNZIONI I, TAVORI H, COVARRUBIAS R.Local effects of human pcsk9 on the atherosclerotic lesion.J Pathol, 6,8(1):52-62.
    [42] BOUCHAREB R, MAHMUT A, NSAIBIA M J.Autotaxin derived from lipoprotein (a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve.Circulation, 5,2(8):677-690.
    [43] ROGERS M A, AIKAWA E.A not-so-little role for lipoprotein (a) in the development of calcific aortic valve disease.Circulation, 5,2(8):621-3.
    [44] NICHOLLS S J, PURI R, ANDERSON T.Effect of evolocumab on coronary plaque composition.J Am Coll Cardiol, 8,2(17):2012-2021.
    [45] MACCHI C, SIRTORI C R, CORSINI A.A new dawn for managing dyslipidemias:the era of rna-based therapies.Pharmacol Res, 9,0:104413.
    [46] ROSENSON R S, HEGELE R A, FAZIO S.The evolving future of pcsk9 inhibitors.J Am Coll Cardio, 8,2(3):314-329.
    [47] GILL P K, HEGELE R A.New biological therapies for low-density lipoprotein cholesterol.Can J Cardiol, 2023, S0828-282X(23):01577-5.
    [48] MALIWAL D, PISSURLENKAR R R, TELVEKAR V.Comprehensive computational study in the identification of novel potential cholesterol lowering agents targeting proprotein convertase subtilisin/kexin type 9.J Biomol Struct Dyn, 3,1-12.
    引证文献
引用本文

龚熙,向琼,陈彦宇,唐志晗,彭娟. PCSK9:心血管钙化的新治疗靶点?[J].中国动脉硬化杂志,2024,32(9):798~804.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2023-10-19
  • 最后修改日期:2023-11-16
  • 在线发布日期: 2024-09-30